Author: eqs

CF PharmTech (HKEX: 2652.HK) Announces NMPA Acceptance of IND Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in PF-ILD

EQS via SeaPRwire.com / 25/02/2026 / 11:12 UTC+8 Suzhou, China, February 24, 2026 — CF PharmTech, Inc. (HKEX: 2652.HK) (“CF PharmTech” or the “Company”) today announced that the Investigational New Drug (“IND”) application for ICF004, the Company’s internally developed first-in-class

More